Search the Newsreel

Is Arcutis (ARQT) Quietly Reframing Its Strategy With Mirum CEO Chris Peetz on the Board?

Arcutis Biotherapeutics recently appointed Mirum Pharmaceuticals CEO Chris Peetz to its Board of Directors, a move that could subtly influence Arcutis's growth and capital allocation strategies. While the immediate focus remains on the ZORYVE franchise and its expanded FDA approval for pediatric plaque psoriasis, …

Arcutis Biotherapeutics (ARQT) Stock Trades At A Discount To Sales But Fair Value Looks Tight

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Arcutis Biotherapeutics stock has delivered a very strong 176.6% return over the past three years, yet the broader valuation checks currently suggest it does not stand out …

Arcutis Biotherapeutics (ARQT) Heads Into Earnings With Its ZORYVE Story Still Shaping Valuation

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Arcutis Biotherapeutics (ARQT) is back in focus as Wall Street looks ahead to its June 2026 quarter earnings report on August 5, with expectations centered on higher …

Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Arcutis Biotherapeutics, Inc. (ARQT) is expected to report a significant year-over-year increase in earnings and revenues for the quarter ending June 2026. The company has a positive Earnings ESP of +52.94% and a Zacks Rank of #2, indicating a high probability of beating the …

Arcutis Biotherapeutics Inc (ARQT) Institutional Confidence

Arcutis Biotherapeutics Inc (ARQT) shows a strong institutional shareholding score of 10.00, ranking 1st in the Pharmaceuticals industry despite a recent quarter-over-quarter decrease of 11.87% in institutional shareholding proportion. Ron Baron is the largest institutional shareholder, holding 1.19M shares. The article also lists other …

Principal Financial Group Inc. Buys Shares of 168,826 Arcutis Biotherapeutics, Inc. $ARQT

ARQT|Arcutis Biotherapeutics Inc|Price:27.860|Chg%:+0.510

This article provides a comprehensive stock analysis of Arcutis Biotherapeutics Inc (ARQT) by TradingKey, highlighting its strong fundamentals, high growth potential, and "Buy" rating from analysts. It details the company's product portfolio, including ZORYVE for psoriasis and atopic dermatitis, and pipeline treatments for alopecia …

Arcutis Biotherapeutics Inc (ARQT) Balance Sheet

This article provides the quarterly and annual balance sheets for Arcutis Biotherapeutics Inc (ARQT), allowing users to assess the company's financial health, analyze fundamentals, and calculate key ratios. It details various assets, liabilities, and shareholder equity components, along with their year-over-year changes. The piece …

Arcutis Biotherapeutics Inc (ARQT) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Arcutis Biotherapeutics Inc (ARQT), allowing users to analyze its financial health. It includes data on operating, investing, and financing cash flows, along with explanations of these financial metrics. The document also presents …

Arcutis Biotherapeutics Inc (ARQT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Arcutis Biotherapeutics Inc (ARQT), focusing on its dividends and stock splits. It states that the company has not distributed any dividends over the past five years. The page also includes current stock prices, market capitalization, and links to …

Arcutis Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:ARQT

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) generated $376.07 million USD in the last year, with its Dermatological Treatments segment being the sole contributor to this revenue. All of the company's revenue originated from the United States and Canada. This figure marks an increase from the $196.54 …

Loss-Making Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Set To Breakeven

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is expected to reach profitability by the end of 2026, with analysts forecasting a mean revenue of US$165.7m for that year. The company's cash runway is estimated to be over two years, alleviating immediate concerns about liquidity. However, investors should …

Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 25.79%: Read This Before Placing a Bet

Arcutis Biotherapeutics, Inc. (ARQT) closed the last trading session at $27.53, gaining 3.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price …

Guggenheim Remains a Buy on Arcutis Biotherapeutics (ARQT)

Guggenheim reiterated a Buy rating for Arcutis Biotherapeutics (ARQT) with a $35.00 price target, following the company's Q1 revenue of $105.4 million and reduced GAAP net loss. While analyst consensus is a Strong Buy, recent insider sentiment has been negative due to increased selling …

Arcutis Biotherapeutics (ARQT) director receives RSUs and stock options

Arcutis Biotherapeutics director Christopher Peetz was granted Restricted Stock Units (RSUs) and stock options on July 15, 2026, as reported in a neutral filing. He received 4,315 RSUs set to vest by June 2027 or the next annual meeting, and stock options for a …

Arcutis Biotherapeutics (ARQT) director trades stock under 10b5-1 plan

Arcutis Biotherapeutics director Howard G. Welgus sold 4,730 shares of common stock at $26.91 per share and exercised stock options to acquire additional shares on July 15, 2026. These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on March 13, 2026. Following …

Arcutis Biotherapeutics director sells $127,284 in stock

Howard G. Welgus, a director at Arcutis Biotherapeutics, Inc., sold 4,730 shares of common stock worth $127,284 on July 15, 2026, under a pre-arranged trading plan. On the same day, he also acquired 4,096 shares through exercising stock options, totaling $32,474. The company has …

Arcutis appoints Christopher Peetz to its board as Class III director

Arcutis has appointed Christopher Peetz as a Class III director to its Board, effective July 15, 2026. This appointment increases the number of authorized directors from nine to ten. Mr. Peetz is the co-founder and CEO of Mirum Pharmaceuticals and has a background in …

Arcutis Biotherapeutics appoints Chris Peetz to board

Arcutis Biotherapeutics has appointed Christopher Peetz, co-founder and CEO of Mirum Pharmaceuticals, to its board of directors, effective July 15, 2026. Peetz brings extensive biopharmaceutical experience from his previous roles at Flashlight Therapeutics, Tobira, Jennerex Biotherapeutics, and Onyx Pharmaceuticals. Arcutis, a commercial-stage immuno-dermatology company, …

Press Release: Arcutis Expands Board of Directors With Appointment of Chris Peetz

Arcutis Biotherapeutics has expanded its Board of Directors with the appointment of Chris Peetz. Mr. Peetz previously served as CEO of Miramar Therapeutics and brings significant pharmaceutical industry leadership experience to Arcutis. His expertise in commercial and financial strategy is expected to be valuable …

Arcutis Biotherapeutics (NASDAQ: ARQT) notice to sell 4730 common shares

Arcutis Biotherapeutics shareholder Howard Welgus plans to sell 4730 common shares through Merrill Lynch on NASDAQ around July 15, 2026, with an estimated market value of $127,284.3. These shares originate from restricted stock vesting and stock option exercises. The filing also details prior sales …

Arcutis schedules Aug. 5 webcast for its business update

Arcutis Biotherapeutics (Nasdaq: ARQT) announced it will report its second quarter 2026 financial results and provide a business update on Wednesday, August 5, 2026, after U.S. markets close. The company will host a conference call and webcast at 4:30 p.m. ET, accessible via the …

Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced it will report its second quarter 2026 financial results and provide a business update on Wednesday, August 5, 2026, after U.S. financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET on …

Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65%

Arcutis Biotherapeutics Q1 Earnings Call Highlights

ARCUTIS BIOTHERAPEUTICS ($ARQT) Releases Q1 2026 Earnings

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates

Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know

Arcutis to give business update with Q1 results after market close May 6

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected